keyword
MENU ▼
Read by QxMD icon Read
search

adjuvant treatment breast cancer

keyword
https://www.readbyqxmd.com/read/29458045/aldose-reductase-inhibitor-fidarestat-prevents-doxorubicin-induced-endothelial-cell-death-and-dysfunction
#1
Himangshu Sonowal, Pabitra Pal, Kirtikar Shukla, Ashish Saxena, Satish K Srivastava, Kota V Ramana
Despite doxorubicin (Dox) being one of the most widely used chemotherapy agents for breast, blood and lung cancers, its use in colon cancer is limited due to increased drug resistance and severe cardiotoxic side effects that increase mortality associated with its use at high doses. Therefore, better adjuvant therapies are warranted to improve the chemotherapeutic efficacy and to decrease cardiotoxicity. We have recently shown that aldose reductase inhibitor, fidarestat, increases the Dox-induced colon cancer cell death and reduces cardiomyopathy...
February 16, 2018: Biochemical Pharmacology
https://www.readbyqxmd.com/read/29455298/patient-reported-predictors-of-early-treatment-discontinuation-treatment-related-symptoms-and-health-related-quality-of-life-among-postmenopausal-women-with-primary-breast-cancer-randomized-to-anastrozole-or-exemestane-on-ncic-clinical-trials-group-cctg-ma
#2
Lynne I Wagner, Fengmin Zhao, Paul E Goss, Judith-Anne W Chapman, Lois E Shepherd, Timothy J Whelan, Bassam I Mattar, Jose A Bufill, William C Schultz, Irving E LaFrancis, Gauri G Nagargoje, Radhakrishna Vemuri, Daniel A Nikcevich, George W Sledge, David Cella
PURPOSE: Aromatase inhibitors are the most commonly prescribed adjuvant endocrine therapy for hormone-dependent early breast cancer in postmenopausal women. Among Canadian Cancer Trials Group MA.27 participants, anastrozole and exemestane had comparable 5-year event-free survival. This companion study examined differences in patient-reported treatment-related symptoms (TRS) and health-related quality of life (HRQL) among postmenopausal women randomized to anastrozole or exemestane. METHODS: MA...
February 17, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29450591/occurrence-of-pneumonitis-following-radiotherapy-of-breast-cancer-a-prospective-study
#3
Danijela Vasiljevic, Christoph Arnold, David Neuman, Katharina Fink, Marina Popovscaia, Irma Kvitsaridze, Meinhard Nevinny-Stickel, Markus Glatzer, Peter Lukas, Thomas Seppi
AIM: of this study is to determine the temporal resolution of therapy-induced pneumonitis, and to assess promoting factors in adjuvant treated patients with unilateral mammacarcinoma. PATIENTS AND METHODS: A total of 100 post-surgery patients were recruited. The cohort was treated by 2 field radiotherapy (2FRT; breast and chest wall, N = 75), 3 field radiotherapy (3FRT; + supraclavicular lymphatic region, N = 8), or with 4 field radiotherapy (4FRT; + parasternal lymphatic region, N = 17)...
February 15, 2018: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/29448311/enhancing-decision-making-about-adjuvant-chemotherapy-in-early-breast-cancer-following-endopredict-testing
#4
Lesley Fallowfield, Lucy Matthews, Shirley May, Valerie Jenkins, David Bloomfield
Chemotherapy side-effects can be substantial. There is increasing recognition that some oestrogen receptor positive (ER+ve), human epidermal growth factor receptor 2 negative (HER2-ve) patients with breast cancer derive no benefit from chemotherapy and experience only iatrogenic harm. Gene expression profiling tests help refine recurrence risk and likely chemotherapy benefit. EndoPredict® is one such test, which classifies risks of distant recurrence as low or high in patients treated with surgery and adjuvant endocrine therapy alone...
February 15, 2018: Psycho-oncology
https://www.readbyqxmd.com/read/29448072/a-phase-iii-study-comparing-sb3-a-proposed-trastuzumab-biosimilar-and-trastuzumab-reference-product-in-her2-positive-early-breast-cancer-treated-with-neoadjuvant-adjuvant-treatment-final-safety-immunogenicity-and-survival-results
#5
X Pivot, I Bondarenko, Z Nowecki, M Dvorkin, E Trishkina, J-H Ahn, S-A Im, T Sarosiek, S Chatterjee, M Z Wojtukiewicz, Y Shparyk, V Moiseyenko, M Bello, V Semiglazov, Y Lee, J Lim
BACKGROUND: The equivalent efficacy between SB3, a proposed trastuzumab biosimilar, and the trastuzumab reference product (TRZ) in terms of the breast pathologic complete response rate after neoadjuvant therapy in patients with early or locally advanced human epidermal growth factor receptor 2-positive breast cancer was demonstrated in the previous report. Here, we report the final safety, immunogenicity and survival results after neoadjuvant-adjuvant treatment. PATIENTS AND METHODS: Patients were randomised 1:1 to receive neoadjuvant SB3 or TRZ for 8 cycles concurrently with chemotherapy (4 cycles of docetaxel followed by 4 cycles of 5-fluorouracil/epirubicin/cyclophosphamide)...
February 12, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29445858/l-thyroxine-intake-as-a-potential-risk-factor-for-the-development-of-fatigue-in-breast-cancer-patients-undergoing-chemotherapy
#6
Martina E Schmidt, Joachim Wiskemann, Theron Johnson, Nina Habermann, Andreas Schneeweiss, Karen Steindorf
PURPOSE: L-Thyroxine is one of the most commonly prescribed drugs and accordingly used by many breast cancer patients with thyroid disorders. Hence, potential interactions of chemotherapy with L-thyroxine, possibly contributing to fatigue, would be of high clinical relevance. Therefore, we investigated fatigue and underlying pathways in L-thyroxine-using breast cancer patients during chemotherapy. METHODS: Thyroid-stimulating hormone (TSH), L-triiodothyronine (T3), and diurnal salivary cortisol patterns were analyzed in breast cancer patients in the beginning and at the end of adjuvant chemotherapy within the control group (n = 41) of a randomized exercise intervention trial...
February 14, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29434896/intra-arterial-interventional-therapy-for-inoperable-local-advanced-breast-cancer-a-retrospective-study
#7
Jing Ma, Jin Song, Hai Chen, Cibo Fan, Jiaqi Xie, Xiaodong Qi
The aim of the present study was to evaluate the safety and efficacy of intra-arterial interventional therapy (IAIT) in the treatment of inoperable local advanced breast cancer (LABC). A total of 7 patients with pathologically proven inoperable LABC were included in the present study. Patients received 1-4 cycles of IAIT prior to mastectomy and postoperative adjuvant therapy. The safety and clinical outcomes of IAIT were retrospectively analyzed. Between February 2009 to September 2016, 7 patients received IAIT...
February 2018: Oncology Letters
https://www.readbyqxmd.com/read/29434476/interest-of-supportive-and-barrier-protective-skin-care-products-in-the-daily-prevention-and-treatment-of-cutaneous-toxicity-during-radiotherapy-for-breast-cancer
#8
Antoine Berger, Carlos Regueiro, Tarek Hijal, David Pasquier, Cristina De La Fuente, Florence Le Tinier, Bernard Coche-Dequeant, Eric Lartigau, Dominique Moyal, Sophie Seité, René-Jean Bensadoun
Purpose: As many as 50% of patients with cancer develop acute skin reactions to some degree with radiotherapy. Proactive skin care is often recommended to minimise these skin reactions and maintain the integrity of the epidermal barrier; nevertheless, no consensual guidelines are systematically used. This multicentre, observational, prospective study evaluated the tolerability and benefit of supportive and barrier protective skin care products in preventing radiotherapy-induced skin reactions in 253 women initiating radiotherapy (exclusive or adjuvant) for breast cancer...
2018: Breast Cancer: Basic and Clinical Research
https://www.readbyqxmd.com/read/29432980/impact-of-timeliness-of-adjuvant-chemotherapy-and-radiotherapy-on-the-outcomes-of-breast-cancer-a-pooled-analysis-of-three-clinical-trials
#9
Omar Abdel-Rahman
OBJECTIVE: To assess the impact of delay in initiation of adjuvant chemotherapy and/or radiotherapy on the outcomes of breast cancer patients referred for adjuvant treatment. METHODS: This is a pooled analysis of patient-level data of 3390 breast cancer patients referred for adjuvant chemotherapy in three clinical trials. Overall and relapse-free survivals were assessed according to "surgery to chemotherapy interval" through Kaplan-Meier analysis. Likewise, among patients who received adjuvant radiotherapy, relapse-free survival was assessed according to "surgery to radiotherapy interval" through Kaplan-Meier analysis...
February 9, 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29428030/longer-time-intervals-from-diagnosis-to-surgical-treatment-in-breast-cancer-associated-factors-and-survival-impact
#10
Margaret Mariella, Charles W Kimbrough, Kelly M McMasters, Nicolas Ajkay
Time interval (TI) from breast cancer diagnosis to definitive surgery is increasing, but the impact on outcomes is not well understood. TI longer than 30 days is associated with a greater chance of delay of chemotherapy, which may impact survival. We sought to identify factors associated with longer TI and the influence on outcome measures. METHODS: We examined TI for stage 0-III breast cancer patients treated between 2006 and 2015 at a university-based cancer center. Univariate and multivariate analyses were used to study factors associated with TI <30, 30 to 60, and >60 days...
January 1, 2018: American Surgeon
https://www.readbyqxmd.com/read/29427213/treatment-strategies-in-octogenarians-with-early-stage-high-risk-breast-cancer
#11
Anita Mamtani, Julie J Gonzalez, Dayna T Neo, Robb S Friedman, Abram Recht, Michele R Hacker, Ranjna Sharma
BACKGROUND: Octogenarians with early-stage breast cancer often have low-risk tumor biology. However, optimal treatment strategies for those with high-risk biology remain unclear. METHODS: We reviewed the records of women ages 80-89 years with biopsy-proven, Stage I-II invasive breast cancer who were referred for surgical evaluation from January 2001 through December 2010. High-risk was defined as human epidermal growth factor receptor-positive (HER2+), triple-negative (TN), or histologic grade 3 disease...
February 9, 2018: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29427202/predictors-of-vasomotor-symptoms-among-breast-cancer-survivors
#12
Katherine W Reeves, Michael Pennell, Randi E Foraker, Carolyn J Crandall, Marcia Stefanick, Electra D Paskett
PURPOSE: Vasomotor symptoms (VMS) are a common side effect of breast cancer treatment, yet modifiable factors that may predict VMS among breast cancer survivors are unknown. METHODS: We estimated multivariable-adjusted odds ratios and 95% confidence intervals (aOR, 95% CI) for predictors of VMS among 3595 breast cancer survivors enrolled in the Life and Longevity after Cancer (LILAC) study, an ancillary study of the Women's Health Initiative (WHI). RESULTS: VMS post-diagnosis were reported by 790 (22...
February 9, 2018: Journal of Cancer Survivorship: Research and Practice
https://www.readbyqxmd.com/read/29425304/associations-between-serum-bone-biomarkers-in-early-breast-cancer-and-development-of-bone-metastasis-results-from-the-azure-big01-04-trial
#13
Janet Brown, Emma Rathbone, Samantha Hinsley, Walter Gregory, Fatma Gossiel, Helen Marshall, Roger Burkinshaw, Helen Shulver, Hasina Thandar, Gianfilippo Bertelli, Keane Maccon, Angela Bowman, Andrew Hanby, Richard Bell, David Cameron, Robert Coleman
Background: Adjuvant therapies can prevent/delay bone metastasis development in breast cancer. We investigated whether serum bone turnover markers in early disease have clinical utility in identifying patients with a high risk of developing bone metastasis. Methods: Markers of bone formation (N-terminal propeptide of type-1 collagen [P1NP]) and bone resorption (C-telopeptide of type-1 collagen [CTX], pyridinoline cross-linked carboxy-terminal telopeptide of type-1 collagen [1-CTP]) were measured in baseline (pretreatment blood samples from 872 patients from a large randomized trial of adjuvant zoledronic acid (AZURE-ISRCTN79831382) in early breast cancer...
February 7, 2018: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29423900/association-between-financial-burden-and-adjuvant-hormonal-therapy-adherence-and-persistent-use-for-privately-insured-women-aged-18-64%C3%A2-years-in-bcbs-of-texas
#14
Junghyun Kim, Suja S Rajan, Xianglin L Du, Luisa Franzini, Sharon H Giordano, Robert O Morgan
PURPOSE: The objective of this study is to understand an impact of financial burden on the adjuvant hormonal therapy (AHT) adherence and persistence for insured women aged 18-64 with early breast cancer in Texas. METHODS: We conducted a retrospective cohort study using claims data for population insured by Blue Cross Blue Shield of Texas from the year 2008 to 2013. Outcomes include adherence to adjuvant hormonal therapy, which was measured by medication possession ratio and persistence on AHT, which is the duration of time from initiation to discontinuation of therapy...
February 8, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29423899/influence-of-control-group-therapy-on-the-benefit-from-dose-dense-chemotherapy-in-early-breast-cancer-a-systemic-review-and-meta-analysis
#15
REVIEW
Hadar Goldvaser, Habeeb Majeed, Domen Ribnikar, Boštjan Šeruga, Alberto Ocaña, David W Cescon, Eitan Amir
PURPOSE: Results from clinical trials of adjuvant dose-dense chemotherapy in patients with breast cancer are inconsistent. METHODS: A systematic search of MEDLINE identified studies comparing the efficacy of dose-dense adjuvant chemotherapy to a standard treatment. The primary analysis included studies that used identical regimens in the experimental and control groups, but varied only dose density. A secondary analysis included studies that used either different drugs or doses in the experimental and the control groups...
February 8, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29423119/meta-analysis-of-three-genome-wide-association-studies-identifies-two-loci-that-predict-survival-and-treatment-outcome-in-breast-cancer
#16
Sofia Khan, Rainer Fagerholm, Latha Kadalayil, William Tapper, Kristiina Aittomäki, Jianjun Liu, Carl Blomqvist, Diana Eccles, Heli Nevanlinna
The majority of breast cancers are driven by the female hormone oestrogen via oestrogen receptor (ER) alpha. ER-positive patients are commonly treated with adjuvant endocrine therapy, however, resistance is a common occurrence and aside from ER-status, no unequivocal predictive biomarkers are currently in clinical use. In this study, we aimed to identify constitutional genetic variants influencing breast cancer survival among ER-positive patients and specifically, among endocrine-treated patients. We conducted a meta-analysis of three genome-wide association studies comprising in total 3,136 patients with ER-positive breast cancer of which 2,751 had received adjuvant endocrine therapy...
January 9, 2018: Oncotarget
https://www.readbyqxmd.com/read/29420220/bq323636-1-a-novel-splice-variant-to-ncor2-as-a-predictor-for-tamoxifen-resistant-breast-cancer
#17
Chun Gong, Ellen Ps Man, Ho Tsoi, Terence K Lee, Paul Lee, Sai-Ting Ma, Lai-San Wong, Mai-Yee Luk, Emad A Rakha, Andrew R Green, Ian O Ellis, Kwok-Leung Cheung, Ui-Soon Khoo
PURPOSE: Adjuvant tamoxifen treatment revolutionized the management of estrogen receptor (ER) positive breast cancers to prevent cancer recurrence; however drug resistance compromises its clinical efficacy. The mechanisms underlying tamoxifen resistance are not fully understood and no robust biomarker is available to reliably predict those who will be resistant. Here we study BQ323636.1, a novel splice variant of the NCOR2 gene and evaluate its efficacy in predicting tamoxifen resistance in breast cancer patients...
February 2, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29419531/differential-prognostic-impact-of-strong-pd-l1-expression-and-18f-fdg-uptake-in-triple-negative-breast-cancer
#18
Seo Hee Choi, Jee Suk Chang, Ja Seung Koo, Jong Won Park, Joo Hyuk Sohn, Ki Chang Keum, Chang-Ok Suh, Yong Bae Kim
OBJECTIVES: Triple-negative breast cancers (TNBC) is an aggressive disease and often associated with early distant metastases, which negate the role of adjuvant radiotherapy. We studied the clinical utility of programmed death ligand-1 (PD-L1) and other available factors in predicting clinical outcome in TNBC. METHODS: Of the 539 patients with newly diagnosed TNBC between 2004 and 2011, we analyzed 117 patients who had both tumor samples which PD-L1 protein expression could be evaluated using immunohistochemistry and initial staging F-fluorodeoxyglucose (FDG) positron emission tomography (PET) data to find available immunologic or metabolic factors...
February 6, 2018: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29416796/cd44-cd24-and-aldehyde-dehydrogenase-1-in-estrogen-receptor-positive-early-breast-cancer-treated-with-tamoxifen-cd24-positivity-is-a-poor-prognosticator
#19
Yong Wha Moon, Hee-Jung An, Ja Seung Koo, Gun Min Kim, Hyunju Han, Seho Park, Seung Il Kim, Hyung Seok Park, Sewha Kim, Seung Ki Kim, Seung Ah Lee, Sohyun Hwang, Gun Woo Son, Joohyuk Sohn
CD44+ /CD24- or aldehyde dehydrogenase 1 (ALDH1) has been suggested as a potential marker for breast cancer stem cells. In the cohort of 819 patients with resected ER-positive breast cancer, the '5-year relapse group' within 5 years postsurgery during adjuvant tamoxifen treatment and the 'non-relapse group' longer than 9 years postsurgery were defined. Paraffin-embedded tumor tissues were available in 31 patients from 5-year relapse group and 68 from the non-relapse group. CD44/ CD24 and ALDH1 expression was evaluated by immunohistochemical staining...
January 5, 2018: Oncotarget
https://www.readbyqxmd.com/read/29416660/foxm1-is-a-promising-candidate-target-in-the-treatment-of-breast-cancer
#20
Xiao-Feng Lu, De Zeng, Wei-Quan Liang, Chun-Fa Chen, Shu-Ming Sun, Hao-Yu Lin
Forkhead box protein M1(FoxM1) is a member of forkhead superfamily transcription factors. Emerging evidences have progressively contributed to our understanding on a central role of FoxM1 in human cancers. However, perspectives on the function of FoxM1 in breast cancer (BC) remain conflicting, and mostly were from basic research. Here, we explored the expression profile and prognostic values of FoxM1 based on analysis of pooled clinical datasets derived from online accessible databases, including ONCOMINE , Breast Cancer Gene-Expression Miner v4...
January 2, 2018: Oncotarget
keyword
keyword
116441
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"